中国医药 - Financials

中国医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	34.1B	38.8B	37.6B	36.2B	39.3B
Revenue Growth %	-12.0%	3.3%	3.8%	-7.8%	--
Total Revenue	34.1B	38.8B	37.6B	36.2B	39.3B
Cost Of Revenue	30.5B	34.4B	32.8B	31.0B	32.5B
+Gross Profit	3.7B	4.4B	4.7B	5.2B	6.8B
Gross Margin %	10.7%	11.3%	12.6%	14.4%	17.3%
Total Operating Cost	33.3B	37.7B	36.5B	35.4B	37.6B
Selling Expenses	1.1B	1.6B	2.0B	2.2B	2.5B
Admin Expenses	975.0M	1.1B	1.0B	885.0M	931.0M
Rd Expenses	125.0M	116.0M	77.3M	57.4M	83.8M
Finance Expenses	196.0M	112.0M	138.0M	222.0M	257.0M
+Operating Income	932.0M	1.7B	1.2B	937.0M	1.9B
Operating Margin %	2.7%	4.3%	3.2%	2.6%	4.9%
Non Operating Income	45.3M	25.4M	14.9M	19.4M	8.9M
Non Operating Expenses	23.6M	57.2M	18.5M	16.4M	22.8M
Investment Income	-65.0M	-15.8M	51.0M	43.7M	37.5M
Fair Value Change Income	127.0M	984,900	1.9M	-2.1M	655,700
Asset Disposal Income	1.7M	437.0M	16.3M	12.2M	637,100
Asset Impairment Loss	175.0M	13.5M	281.0M	575.0M	683.0M
Other Income	64.9M	84.5M	46.7M	75.8M	141.0M
Income Before Tax	953.0M	1.6B	1.2B	940.0M	1.9B
Income Tax	267.0M	398.0M	308.0M	226.0M	539.0M
+Net Income	687.0M	1.2B	888.0M	714.0M	1.4B
Net Margin %	2.0%	3.2%	2.4%	2.0%	3.5%
Net Income Attributable	535.0M	1.0B	736.0M	647.0M	1.3B
Minority Interest	151.0M	194.0M	153.0M	67.2M	75.4M
Eps Basic	0.36	0.70	0.49	0.43	1.23
Eps Diluted	0.36	0.70	0.49	0.43	1.23

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	4.4B	3.9B	4.3B	2.8B	3.6B
Trading Financial Assets	129.0M	--	--	--	16.3M
Accounts Receivable	13.0B	13.8B	13.2B	11.2B	11.1B
Notes Receivable	544.0M	311.0M	345.0M	97.8M	79.2M
Notes And Accounts Receivable	13.6B	14.2B	13.5B	11.3B	11.2B
Prepayments	728.0M	848.0M	1.2B	580.0M	1.0B
Inventory	6.3B	6.2B	6.1B	5.7B	6.8B
Total Current Assets	27.4B	28.5B	26.9B	22.2B	25.1B
Long Term Equity Investment	2.7B	2.6B	2.6B	2.5B	2.4B
Fixed Assets	--	2.3B	2.3B	2.2B	1.5B
Fixed Assets Total	2.2B	2.3B	2.3B	2.2B	1.5B
Construction In Progress	--	192.0M	197.0M	414.0M	954.0M
Construction In Progress Total	258.0M	196.0M	201.0M	418.0M	965.0M
Intangible Assets	678.0M	604.0M	486.0M	425.0M	376.0M
Long Term Deferred Expenses	152.0M	158.0M	118.0M	82.7M	84.1M
Total Non Current Assets	8.9B	8.9B	9.0B	8.9B	8.1B
Total Assets	36.3B	37.4B	35.9B	31.1B	33.2B
Short Term Borrowings	4.0B	2.2B	998.0M	1.5B	2.6B
Accounts Payable	7.2B	8.6B	7.6B	5.4B	5.5B
Advance Receipts	1.4M	5.7M	4.9M	5.2M	4.7M
Contract Liabilities	1.1B	1.4B	2.0B	1.4B	3.6B
Total Current Liabilities	18.0B	18.0B	18.0B	13.5B	17.1B
Long Term Borrowings	1.6B	2.5B	2.2B	3.0B	1.9B
Total Non Current Liabilities	4.0B	5.5B	4.7B	5.1B	3.8B
Total Liabilities	22.0B	23.5B	22.7B	18.6B	21.0B
Paid In Capital	1.5B	1.5B	1.5B	1.1B	1.1B
Capital Reserve	2.1B	2.0B	2.1B	2.0B	2.0B
Surplus Reserve	631.0M	604.0M	579.0M	549.0M	549.0M
Retained Earnings	7.8B	7.4B	6.7B	6.6B	6.3B
Minority Equity	2.3B	2.3B	2.4B	2.3B	2.2B
Equity Attributable	12.0B	11.6B	10.8B	10.3B	10.0B
Total Equity	14.3B	13.9B	13.2B	12.5B	12.2B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	35.3B	40.2B	38.6B	34.6B	42.1B
Tax Refunds Received	127.0M	179.0M	262.0M	258.0M	681.0M
Total Operating Cash Inflow	36.2B	41.7B	40.7B	36.6B	44.7B
Cash Paid For Goods	31.3B	34.6B	33.2B	30.1B	36.4B
Cash Paid To Employees	1.5B	1.4B	1.3B	1.3B	1.2B
Taxes Paid	937.0M	2.0B	1.2B	1.3B	1.4B
Total Operating Cash Outflow	35.2B	40.9B	39.1B	36.4B	43.2B
Operating Cash Flow	1.0B	859.0M	1.6B	148.0M	1.6B
Total Investing Cash Inflow	43.8M	46.3M	292.0M	171.0M	346.0M
Total Investing Cash Outflow	411.0M	363.0M	270.0M	426.0M	674.0M
Investing Cash Flow	-368.0M	-316.0M	22.1M	-254.0M	-328.0M
Cash From Borrowings	6.4B	3.9B	3.3B	2.7B	8.4B
Dividends And Interest Paid	589.0M	433.0M	416.0M	582.0M	530.0M
Debt Repayments	5.5B	3.7B	2.6B	2.7B	7.9B
Total Financing Cash Inflow	6.5B	3.9B	4.0B	2.9B	9.5B
Total Financing Cash Outflow	6.8B	4.6B	4.1B	3.7B	9.9B
Financing Cash Flow	-258.0M	-726.0M	-2.0M	-729.0M	-366.0M
Net Change In Cash	381.0M	-181.0M	1.7B	-839.0M	856.0M
Ending Cash Balance	3.7B	3.3B	3.5B	1.8B	2.7B
Capex	359.0M	363.0M	229.0M	286.0M	318.0M